US lawmakers’ arguments over the details of coronavirus economic relief legislation could have opened a door for passage of the OTC drug industry’s top regulatory priorities – reforming the monograph drug program and allowing purchases of nonprescription drugs with pre-tax health savings accounts.
The latest text for Senate pandemic relief legislation would impose both regulatory changes following an agreement between Senate Democrats and the White House
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?